[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352955-105":59,"doc-detail-352955-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ensemble-optimal-control-for-managing-drug-resistance-in-cancer-therapies","Ensemble Optimal Control for Managing Drug Resistance in Cancer Therapies","","Ensemble Optimal Control is applied to design improved pharmacological strategies for long-term cancer management when complete tumor eradication is not feasible. The work moves beyond the maximal tolerated drug (MTD) paradigm by exploiting the interaction between sensitive and resistant cell subpopulations under limited resources. A Lotka–Volterra competing-population model is embedded in an ensemble-control framework. General results are developed and numerical simulations for prostate cancer under androgen deprivation therapy are used to derive a policy resembling medical active surveillance. Based on these findings, an “Off-On” adaptive-therapy variant is proposed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ensemble-optimal-control-for-managing-drug-resistance-in-cancer-therapies/352955/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ensemble-optimal-control-for-managing-drug-resistance-in-cancer-therapies/352955.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the paper go beyond the maximal tolerated drug (MTD) approach?","Question",{"text":112,"@type":113},"MTD does not adequately leverage the competitive dynamics between sensitive and resistant cells under available resources. The paper instead seeks strategies that account for these interactions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What model framework is used to represent sensitive and resistant cancer subpopulations?",{"text":117,"@type":113},"The paper uses a Lotka–Volterra model for competing subpopulations, then embeds this system into an ensemble control framework.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the proposed control relate to active surveillance in the prostate-cancer simulation?",{"text":121,"@type":113},"Numerical simulations yield a computed policy that resembles the medical “active surveillance” paradigm.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352955,1790193952,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Bulletin of Mathematical Biology (2026) 88:92  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1)1538-026-01661-z  \nORIGINAL ARTICLE  \nEnsemble Optimal Control for Managing Drug Resistance in Cancer Therapies  \nAlessandro Scagliotti1,2 · Federico Scagliotti3,4 · Laura Deborah Locati3,4 · Federico Sottotetti3  \nReceived: 18 November 2025 / Accepted: 6 May 2026 / Published online: 21 May 2026 © The Author(s) 2026  \nAbstract  \nIn thispaper, we explore the application ofensemble optimal control to derive enhanced strategies for pharmacological cancer treatment, and we tackle the problem ofthe longterm management ofthe disease, i.e., when the complete eradication ofthe tumor isnot achievable. In particular, we focus on moving beyond the classical clinical approach of giving the patient the maximal tolerated drug dose (MTD), which does not properly exploit the ﬁght among sensitive and resistant cells for the available resources. Here, we employ a Lotka-Volterra model to describe the competing subpopulations, and we enclose this system within the ensemble control framework. In the ﬁrst part, we establish general results suitable for application to various cancers. Then, we carryout numerical simulations in the setting of prostate cancer treated with androgen deprivation therapy, yielding a computed policy that is reminiscent of the medical‘active surveillance’paradigm. Finally, inspiredby the numerical evidence, we propose a variant of the celebrated adaptive therapy (AT), which we call ‘Off-On’ AT.  \nKeywords Ensemble optimal control · Cancer modeling · Drug resistance management · Gradient-based optimization  \nLaura Deborah Locati and Federico Sottotetti, have contributed equally to this work  \nB Alessandro Scagliotti[scag@ma.tum.de](scag@ma.tum.de)  \nFederico Scagliotti  \n[federico.scagliotti@icsmaugeri.it](federico.scagliotti@icsmaugeri.it)  \nLaura Deborah Locati  \n[lauradeborah.locati@unipv.it](lauradeborah.locati@unipv.it)  \nFederico Sottotetti  \n[federico.sottotetti@icsmaugeri.it](federico.sottotetti@icsmaugeri.it)  \n1 CIT School, Technical University of Munich, Boltzmannstr. 3/II, Garching bei München 85748, Germany  \n2 Munich Center for Machine Learning (MCML), Munich, Germany  \n3 Medical Oncology Unit, Istituti Clinici Scientiﬁci Maugeri IRCCS, Pavia, Italy  \n4 Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy  \nMathematics Subject Classiﬁcation 49M25 · 49M05 · 92C50 · 49J45  \n1 Introduction  \nIn this paper, we consider a simple differential model for drug resistance in pharmacological cancer treatments, and we address the uncertainty that affects the dynamicsand the Cauchy datum using tools of ensemble control of ODEs.  \nWe recall that, given a time horizon T > 0, an ensemble of control systems in Rn is a family of controlled ODEs of the form  \n􀀂 x˙xθθ ((t0))  Gxθθ0 ,􀀃t , x θ (t ), u (t )􀀄 a.e. in [0 , T], (1.1)  \nwhere u: [0 , T] → Rm is the m-dimensional control input,[0 , T] 􀀃 t 􀀄→ x θ (t ) ∈ Rn is the corresponding trajectory, and where the dynamics Gθ : [0 , T]×Rn ×Rm → Rnand the initial condition xθ0 depend continuously on the (unknown) k-dimensional parameter θ, which varies in a compact set 􀀃 ⊂ Rk. In this framework, we aim to ﬁnd a common policy t 􀀄→ u (t ) for simultaneously driving every system of the parametrized family (1.1) . This is typically the case when the parameters that appear in the dynamics are subject to statistical errors, and we seek to compute a control that works in every situation (see Ruths and Li 2012) . Problems involving ensembles are a timely source of interest for researchers working in Mathematical Control. Indeed, on the one hand, among the recent theoretical contributions in theﬁeld, wereport(Aronna et al. 2025b; Bettiol and Khalil 2019, 2024) for averaged optimal control problems, and Abdel Wahab and Bettiol (2025); Scagliotti (2025) for the minimax optimization. Moreover, the Hamilton-Jacobi-Bellman equation related to ensemble control","cbCaikIvWjjRq3Tz","https://ap.wps.com/l/cbCaikIvWjjRq3Tz","pdf",983256,35,"English","# Abstract\n# Keywords\n# Introduction\n## Ensemble control of ODEs under parameter uncertainty\n## Motivation and related work\n# Mathematics Subject Classification","[{\"question\":\"Why does the paper go beyond the maximal tolerated drug (MTD) approach?\",\"answer\":\"MTD does not adequately leverage the competitive dynamics between sensitive and resistant cells under available resources. The paper instead seeks strategies that account for these interactions.\"},{\"question\":\"What model framework is used to represent sensitive and resistant cancer subpopulations?\",\"answer\":\"The paper uses a Lotka–Volterra model for competing subpopulations, then embeds this system into an ensemble control framework.\"},{\"question\":\"How does the proposed control relate to active surveillance in the prostate-cancer simulation?\",\"answer\":\"Numerical simulations yield a computed policy that resembles the medical “active surveillance” paradigm.\"}]","Ensemble Optimal Control for Managing Drug Resistance in Cancer Therapies | PDF",1790102307,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e96934ffaff5668b41c1f64458900bc.webp",983,1415,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ba8a87781e8bafc596c47f365fa29df.webp",982,1414,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d21fdf8324057b3e5dc4d8b4609a90c3.webp",981,1412,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7641e154eb68e616742a4cd2fcaad26.webp",980,1411]